Long-term survival of a patient with primary papillary serous carcinoma of the peritoneum treated by subtotal peritonectomy plus intraoperative chemohyperthermia

Hepatogastroenterology. 2002 Jul-Aug;49(46):1027-9.

Abstract

We report the long-term survival of a patient with primary papillary serous carcinoma of the peritoneum, treated by subtotal peritonectomy combined with continuous hyperthermic peritoneal perfusion. After subtotal peritonectomy and continuous hyperthermic peritoneal perfusion, early postoperative intraperitoneal chemotherapy with cisplatin and three cycles of cisplatin-based intravenous chemotherapy were administered. The patient currently remains alive 23 months after surgery. This long-term survival suggests that treatment of primary papillary serous carcinoma of the peritoneum requires aggressive cytoreduction surgery followed by chemotherapy using adequate methods to enhance chemosensitivity.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Chemotherapy, Cancer, Regional Perfusion / methods*
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Combined Modality Therapy
  • Cystadenocarcinoma, Papillary / drug therapy
  • Cystadenocarcinoma, Papillary / mortality
  • Cystadenocarcinoma, Papillary / pathology
  • Cystadenocarcinoma, Papillary / surgery*
  • Diagnosis, Differential
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperthermia, Induced / methods*
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / pathology
  • Peritoneal Neoplasms / surgery*
  • Peritoneum / pathology
  • Peritoneum / surgery
  • Survival Rate
  • Survivors

Substances

  • Cisplatin